C-reactive protein, vitamin B12 and C677T polymorphism of N-5,10-methylenetetrahydrofolate reductase gene are related to insulin resistance and risk factors for metabolic syndrome in Chinese population

Clinical and Investigative Medicine

Volumn 33, Issue 5, 2010, Pages

  Chen, Ai Rong ^a,b   Zhang, Hong Gang ^a,b   Wang, Zhi Ping ^a   Fu, Sheng Jun ^a   Yang, Pei Qi ^a   Ren, Jian Gong ^a,b   Ning, Ying Yuan ^a,b   Hu, Xue Jian ^a,b   Tian, Ling Hong ^a,b  

^a LANZHOU UNIVERSITY   (China)

^b Key Department for Diabetes Mellitus of Gansu Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYANOCOBALAMIN; FOLIC ACID; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

AGED; ARTICLE; ASIAN; BLOOD; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; RADIOIMMUNOASSAY;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; C-REACTIVE PROTEIN; FEMALE; FOLIC ACID; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; RADIOIMMUNOASSAY; VITAMIN B 12;

EID: 77957875122     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Tyagi SC: Homocyst(e)ine and heart disease: Patho-physiology of extracellular matrix. Clin Exp Hypertens 1999, 21(3):181-198.
2. Mitraoui N, Ezzidi I, Chaieb M, Marmouche H, Aouni Z, Chaieb A, Mahjouba T,Vaxillairec M, Almawi WY. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic neph-ropathy in type 2 diabetes patients. Diabetes Res Clin Pract 2007;75:99-106.
3. Neugebauer S, Baba T, Watanabe T. Methylenetrahy-drofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998;352:454.
4. Hayden MR, Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: The pleiotropic effects of folate supplementation. Nutr J 2004;3:4-27.
5. Hajer GR, van der Graaf Y, Olijhoek JK, Verhaar MC, Visseren FL. Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome. Heart 2007;93:216-220.
6. Loria CM, Ingram DD, Feldman JJ, Wright JD, Ma-dans JH. Serum folate and cardiovascular disease mortality among US men and women. Arch Intern Med 2000;160:3258-3262.
7. Bazzano LA, Reynolds K, Holder KN, He Jiang. Effect of folic acid supplementation on risk of cardiovascular diseases. A meta analysis of randomized controlled trials. JAMA 2006;296:2720-2726.
8. Tokgozoglu SL, Alikasifoglu M, Unsal, Atalar E, Aytemir K, Ozer N, et al. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate. Heart 1999;81:518-522.
9. Meigs JB, Fox CS, Rutter MK, D'Agostino RB, Sullivan LM, Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes care. 2007;30:1219-1225.
10. Anna Malinowska, Agata Chmurzynska. Polymorphism of genes encoding homocysteine metabolism-related enzymes and risk for cardiovascular disease, Nutrition Research 2009; 29: 685-695
11. Chen AR, Ning YY, Zhu XZ, Li LY, Shi H. Study on the relationship between N5,10-methylenetetrahydrofolate reductase gene polymorphisms and nephropathy in type 2 diabetes mellitus in Gansu Han of China. Chinese Journal of Prevention and Control of Chronic Non-Communicable Diseases 2004;12:195-197.
12. Sun JZ, Xu YZ, Zhu YL, Lu HY, Deng HH, Fan YY, Sun SX, Zhang Y. The relationship between MTHFR gene polymorphisms, plasma homocysteine levels and diabetic retinopathy in type 2 diabetes mellitus. Chin Med J 2003;116:145-147.
13. Metabolic Syndrome Research Cooperation Group of Chinese Medical Association Diabetes Branch. Recommendation of Metabolic Syndrome by Chinese Medical Association Diabetes Branch. Chin J Diabetes 2004;12:156-161.
14. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG. A candidate genetic risk factor for vascular disease:a common mutation in methykenetetra-hydrofolate reductase. Nat Genet 1995;10:111-113.
15. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006; 21:1-6.
16. Kim WY, Kim JE, Choi YJ, Huh KB. Nutritional risk and metabolic syndrome in Korean type 2 diabetes mellitus. Asia Pac J Clin Nutr 2008;17 Suppl 1:47-51.
17. Misra A, Misra R, Wijesuriya M, Banerjee D. The metabolic syndrome in South Asians: continuing escalation & possible solutions. Indian J Med Res 2007;125:345-354.
18. Subbiah MT. Nutrigenetics and nutraceuticals: the next wave riding on personalizedmedicine. Translational Research 2007;149:55-61.
19. Hanson HQ, Aras O, Yang F, Tsai MY. C677T and A1298C polymorphisms of methylene tetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 2001;47:661-466.
20. Molloy AM, Scott JM. Folates and prevention of disease. Public Health Nutr 2001; 4:601-609.
21. Golbahar J, Aminzadeh MA, Al-Shboul QM, Kassab S, Rezaian GR. Association of methylenetetrahydrofolate reductase (C677T) polymorphism with hyperuricemia. Nutrition, Metabolism & Cardiovascular Diseases 2007;17:462-467.
22. Motti C, Gnasso A, Bernardini S, Massoud R, Pastore A, Rampa P, Press RD. Common mutation in methyle-netetrahydrofolate reductase Correlation with homo-cysteine and other risk factors for vascular disease. Atherosclerosis 1998; 139:377-383.
23. Lwin H, Yoshiike N, Yokoyama T, Saito K, Date C, Tanaka H. The relationships between plasma total homocysteine and selected atherosclerotic risk factors according to the C677T methylenetetrahydrofolate re-ductase gene in Japanese. Eur J Cardiovasc Prev Reha-bil 2005;12:182-184.
24. Ghazouani L, Abboud N, Mtiraoui N, Zammiti W, Ad-dad F, Amin H, Almawi WY, Mahjoub T. Homocys-teine and methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in Tunisian patients with severe coronary artery disease. J Thromb Thrombolysis 2008;27:191-197.
25. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol Clin 2003;21:315-325.
26. Araki A, Hosoi T, Orimo H, Ito H. Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes. Metabolism 2005; 54: 809-814.
27. Onat A, Hergenc G, Kucukdurmaz Z, Can G, Ayhan E, Bulur S. Serum folate is associated with coronary heart disease independently of homocysteine in Turkish men. Clin Nutr 2008;27:732-739.
28. Chien-Hsiang Chenga, Tsung-Po Tsaib,c, Wan-Shin Chend, Yi-Chia Huange.Serum folate is a reliable indicator of hyperhomocysteinemia and borderline hy-perhomocysteinemia in young adults. Nutrition Research 29 (2009) 743-749.
29. Setola E, Monti LD, Galluccio E, Palloshi A, Fragasso G, Paroni R. Insulin resistance and endothelial function are improved after folate and vitamin B12 therapy in patients with metabolic syndrome: relationship between homocysteine levels and hyperinsulinemia. Eur J Endocrinology 2004;151:483-489.
30. Chambers JC, Ueland PM, Obeid OA, Wrigly J, Ref-sum H, Kooner JS. Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homo-cysteine. Circulation 2000;102: 2479-2483.
31. Allen RH, Stabler SP. Hyperhomocysteinemia and vitamin B-12 deficiency in elderly using Title IIIc nutrition services. Am J Clin Nutr 2003;77:211-220.
32. Liaugaudas G, Jacques PF, Selhub J, Rosenberg IH, Bostom AG. Renal insufficiency, vitamin B(12) status, and population attributable risk for mild hyperhomo-cysteinemia among coronary artery disease patients in the era of folic acid-fortified cereal ngrain flour. Arte-rioscler Thromb Vasc Biol 2001; 21:849-851.
33. Homocysteine Lowering Trialists' Collaboration: Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ 1998, 316:894-898.
34. Johnson MA, Hawthorne NA, Brackett WR, Fischer JG, Gunter EW, Allen RH, Stabler SP: Hyperhomocys-teinemia and vitamin B-12 deficiency in elderly using Title IIIc nutrition services. Am J Clin Nutr 2003, 77(1):211-220.